Multivesicular Liposomes for Prostate Volume Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Benign Prostatic Hyperplasia (BPH) are limited by side effects and inefficiencies, as existing drugs and surgeries either relieve symptoms without reducing prostate size or take a long time to show results, and often come with sexual side effects or surgical complications.
Innovation Solution
Development of multivesicular liposomes containing a hyaluronan-degrading enzyme, such as hyaluronidase, for sustained release formulations that target and degrade hyaluronic acid in the prostate stroma, leading to selective apoptosis of stromal cells and reduction in prostate size without affecting epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs or surgeries are used to treat BPH, then prostate size may be reduced or symptoms relieved, but sexual side effects occur or surgical complications arise
Solution Approach 1:
The invention segments the therapeutic action by using multivesicular liposomes to deliver hyaluronidase specifically to the stromal compartment of the prostate, separating the effect on stromal cells from epithelial cells. This targeted delivery achieves prostate volume reduction without the systemic sexual side effects associated with conventional BPH medications.
Solution Approach 2:
The multivesicular liposome acts as an intermediary carrier that protects hyaluronidase and enables targeted delivery to the prostate stroma. This intermediary system allows the enzyme to reach its target selectively, reducing harmful systemic effects while maintaining therapeutic efficacy.
2Productivity
If conventional treatments are used for BPH, then symptoms may be relieved, but treatment time is prolonged with delayed results
Solution Approach 1:
The invention changes the parameter of drug delivery by using multivesicular liposomes that provide sustained release of hyaluronidase, maintaining therapeutic concentrations over time. This results in faster and more consistent prostate volume reduction compared to conventional treatments, with significant effects observed within weeks rather than months.
3Reliability
If hyaluronan-degrading enzyme is administered without specialized formulation, then enzyme activity may be lost, but formulation complexity increases
Solution Approach 1:
The invention uses a nested structure where hyaluronidase is encapsulated within inner vesicles, which are themselves contained within multivesicular liposomes. This nested formulation protects the enzyme from degradation and maintains activity while providing a systematic approach to drug delivery that is scalable and manufacturable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of hyaluronan-degrading enzymes in multivesicular liposomes provides a safe and effective method to reduce prostate volume rapidly, with no sexual side effects and minimal tissue exposure, offering a distinct therapeutic approach that halts BPH progression and promotes prolonged focal hydrolysis of hyaluronic acid.
Implementation Method 1
promotes prolonged focal hydrolysis of hyaluronic acid
Data Source
AI summary
Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.